Seagen is a publicly listed company tracked for investment-relevant business developments.
Seagen's antibody-drug conjugate (ADC) technology — four marketed products and 13 clinical programs — represents a 'precision missile' approach to cancer therapy that can target multiple tissues and payloads, making it one of Pfizer's most promising acquisitions if the platform delivers on its combinatorial potential.